Vincerx in Selloff After Early-stage Data for Cancer Therapy

Seeking AlphaApr 9 08:54 ET

AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu

British drugmaker AstraZeneca (AZN.L, AZN.ST) and Japanese partner Daiichi Sankyo scored new regulatory wins for their jointly developed cancer treatment Enhertu in the US, according to a Monday release.

MT NewswiresApr 8 04:35 ET

AstraZeneca, Daiichi Sankyo's Solid Tumor Drug Wins US FDA's Accelerated Approval

AstraZeneca (AZN.L, AZN.ST) secured accelerated approval for its antibody drug conjugate Enhertu, co-developed with Daiichi Sankyo (D4S.F), for treating adult patients with unresectable or metastatic HER2-positive solid tumors in the US.

MT NewswiresApr 8 02:49 ET

AstraZeneca's Enhertu Granted Approval for HER-2 Positive Tumor-agnostic Indications

Seeking AlphaApr 5 16:14 ET

FDA Accepts Daiichi Sankyo-AstraZeneca's Breast Cancer Therapy for Review

Seeking AlphaApr 2 08:16 ET

Two Datopotamab Deruxtecan Applications Validated in the EU for Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer

Yahoo FinanceMar 4 02:00 ET